Awfis Space Solutions grants 3,116 employee stock options

Awfis Space Solutions Limited has announced the approval of the grant of 3,116 employee stock options under its ‘Awfis Space Solutions Employee Stock Option Scheme – 2024’. The Nomination and Remuneration Committee (NRC) considered and approved this grant on November 03, 2026. The options are priced at an exercise price of INR 168.99 per option, representing a 30% discount on the preceding trading day’s market price.

Employee Stock Option Grant Approved

Awfis Space Solutions Limited has officially announced the approval of a grant of 3,116 Employee Stock Options (ESOPs) under its ‘Awfis Space Solutions Employee Stock Option Scheme – 2024’. This significant decision was made by the Nomination and Remuneration Committee (NRC) of the company during its meeting held on November 03, 2026.

Grant Details and Pricing

The granted options are part of the company’s employee incentive program aimed at aligning employee interests with shareholder value. The NRC has set an exercise price of INR 168.99 per option. This price reflects a 30% discount from the average market price of the company’s shares on the preceding trading day, which was November 02, 2026.

Scheme and Vesting Information

The ‘Scheme’ provides for a vesting period of Four Years, with 25% of the options vesting upon the completion of each 12-month period. The grant date for these options is November 03, 2026. In the event of continuous employment, all vested options shall be exercisable within a maximum of two years from the respective vesting date. Specific terms for cessation of employment, including death, permanent incapacity, and categorization as a ‘Good Leaver’ or ‘Bad Leaver’, are detailed within the scheme documents, with provisions for option lapsing or continued vesting based on the circumstances.

Corporate Filings and Disclosures

This disclosure has been made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The details of the grant are annexed in Annexure – A, providing a comprehensive overview of the scheme and its implications. The company will also make this information available on its website for public access.

Source: BSE

Previous Article

Emcure Pharmaceuticals reports 29% PAT growth in Q2 FY27